The Story
News Summary
- TCW's Q2 2026 letter reviews market gains driven by AI capex and earnings, but flags Boston Scientific's underperformance due to weak Watchman/EP results and lowered 2026 guidance despite positive CHAMPION-AF trial data.
Explore US500 price history & advisor snapshot
These are separate market snapshots and may predate this story. Check the data period, generation time and expiry before using them in your research.
Stored market data
US500 price history
7619.98
+12.62% over the displayed period
Advisor Snapshot
Unlock Member-Only Insights
Reserved for TradingNews24 members. Log in or create a free account to access market signals and exclusive tools.